Clinical Trials in Arizona

Showing 721-740 of 8,032 trials

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

NCT06621602

This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.

REM Behavior DisorderParkinson Disease

CND Life Sciences100 participantsStarted Dec 2024

Scottsdale, Arizona, United States • Scottsdale, Arizona, United States • Aliso Viejo, California, United States +15 more locations

RECRUITINGPHASE331 miles

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823

This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.

Hereditary Angioedema (HAE)

Astria Therapeutics, Inc.145 participantsStarted Mar 2025

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Little Rock, Arkansas, United States +76 more locations

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

A Study of Navenibart in Participants With Hereditary Angioedema

Find Trials by Condition in Arizona

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

Amplatzer Amulet LAAO vs. NOAC

A Study of AZD0120 in Autoimmune Diseases

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Galleri® in the Medicare Population.

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Study of ATX-01 in Participants With DM1

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies